vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and MAXLINEAR, INC (MXL). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $137.2M, roughly 1.4× MAXLINEAR, INC). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -32.9%, a 33.8% gap on every dollar of revenue. On growth, MAXLINEAR, INC posted the faster year-over-year revenue change (43.0% vs 23.7%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 22.1%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
MaxLinear, Inc. is an American electronic hardware company. Founded in 2003, it provides highly integrated radio-frequency (RF) analog and mixed-signal semiconductor products for broadband communications applications. It is a New York Stock Exchange-traded company.
FOLD vs MXL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $137.2M |
| Net Profit | $1.7M | $-45.1M |
| Gross Margin | 85.7% | 57.5% |
| Operating Margin | 8.6% | 30.0% |
| Net Margin | 0.9% | -32.9% |
| Revenue YoY | 23.7% | 43.0% |
| Net Profit YoY | -88.5% | -203.0% |
| EPS (diluted) | $0.00 | $-0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $137.2M | ||
| Q4 25 | $185.2M | $136.4M | ||
| Q3 25 | $169.1M | $126.5M | ||
| Q2 25 | $154.7M | $108.8M | ||
| Q1 25 | $125.2M | $95.9M | ||
| Q4 24 | $149.7M | $92.2M | ||
| Q3 24 | $141.5M | $81.1M | ||
| Q2 24 | $126.7M | $92.0M |
| Q1 26 | — | $-45.1M | ||
| Q4 25 | $1.7M | $-14.9M | ||
| Q3 25 | $17.3M | $-45.5M | ||
| Q2 25 | $-24.4M | $-26.6M | ||
| Q1 25 | $-21.7M | $-49.7M | ||
| Q4 24 | $14.7M | $-57.8M | ||
| Q3 24 | $-6.7M | $-75.8M | ||
| Q2 24 | $-15.7M | $-39.3M |
| Q1 26 | — | 57.5% | ||
| Q4 25 | 85.7% | 57.6% | ||
| Q3 25 | 88.5% | 56.9% | ||
| Q2 25 | 90.2% | 56.5% | ||
| Q1 25 | 90.7% | 56.1% | ||
| Q4 24 | 90.1% | 55.6% | ||
| Q3 24 | 90.6% | 54.4% | ||
| Q2 24 | 91.1% | 54.6% |
| Q1 26 | — | 30.0% | ||
| Q4 25 | 8.6% | -10.9% | ||
| Q3 25 | 20.3% | -32.7% | ||
| Q2 25 | -6.1% | -22.6% | ||
| Q1 25 | -6.3% | -48.0% | ||
| Q4 24 | 10.7% | -44.7% | ||
| Q3 24 | 15.3% | -82.3% | ||
| Q2 24 | 11.8% | -44.4% |
| Q1 26 | — | -32.9% | ||
| Q4 25 | 0.9% | -10.9% | ||
| Q3 25 | 10.2% | -36.0% | ||
| Q2 25 | -15.8% | -24.4% | ||
| Q1 25 | -17.3% | -51.8% | ||
| Q4 24 | 9.8% | -62.8% | ||
| Q3 24 | -4.8% | -93.4% | ||
| Q2 24 | -12.4% | -42.7% |
| Q1 26 | — | $-0.52 | ||
| Q4 25 | $0.00 | $-0.17 | ||
| Q3 25 | $0.06 | $-0.52 | ||
| Q2 25 | $-0.08 | $-0.31 | ||
| Q1 25 | $-0.07 | $-0.58 | ||
| Q4 24 | $0.05 | $-0.68 | ||
| Q3 24 | $-0.02 | $-0.90 | ||
| Q2 24 | $-0.05 | $-0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $61.1M |
| Total DebtLower is stronger | $392.7M | $123.8M |
| Stockholders' EquityBook value | $274.2M | $454.2M |
| Total Assets | $949.9M | $771.3M |
| Debt / EquityLower = less leverage | 1.43× | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $61.1M | ||
| Q4 25 | $293.5M | $72.8M | ||
| Q3 25 | $263.8M | $111.9M | ||
| Q2 25 | $231.0M | $108.6M | ||
| Q1 25 | $250.6M | $102.8M | ||
| Q4 24 | $249.9M | $118.6M | ||
| Q3 24 | $249.8M | $148.5M | ||
| Q2 24 | $260.1M | $185.1M |
| Q1 26 | — | $123.8M | ||
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — |
| Q1 26 | — | $454.2M | ||
| Q4 25 | $274.2M | $451.9M | ||
| Q3 25 | $230.4M | $464.7M | ||
| Q2 25 | $204.3M | $488.3M | ||
| Q1 25 | $193.6M | $493.2M | ||
| Q4 24 | $194.0M | $516.3M | ||
| Q3 24 | $178.8M | $556.9M | ||
| Q2 24 | $132.5M | $617.3M |
| Q1 26 | — | $771.3M | ||
| Q4 25 | $949.9M | $796.4M | ||
| Q3 25 | $868.8M | $808.1M | ||
| Q2 25 | $815.3M | $863.7M | ||
| Q1 25 | $789.8M | $855.3M | ||
| Q4 24 | $785.0M | $864.6M | ||
| Q3 24 | $786.6M | $895.3M | ||
| Q2 24 | $749.5M | $973.2M |
| Q1 26 | — | 0.27× | ||
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | — |
| Free Cash FlowOCF − Capex | $16.0M | — |
| FCF MarginFCF / Revenue | 8.6% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 9.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $16.3M | $10.4M | ||
| Q3 25 | $35.7M | $10.1M | ||
| Q2 25 | $-26.5M | $10.5M | ||
| Q1 25 | $7.8M | $-11.4M | ||
| Q4 24 | $-3.9M | $-27.8M | ||
| Q3 24 | $-23.0M | $-30.7M | ||
| Q2 24 | $22.7M | $-2.7M |
| Q1 26 | — | — | ||
| Q4 25 | $16.0M | $6.7M | ||
| Q3 25 | $35.3M | $4.4M | ||
| Q2 25 | $-28.9M | $9.3M | ||
| Q1 25 | $7.5M | $-13.4M | ||
| Q4 24 | $-4.2M | $-30.0M | ||
| Q3 24 | $-23.3M | $-34.9M | ||
| Q2 24 | $21.6M | $-5.7M |
| Q1 26 | — | — | ||
| Q4 25 | 8.6% | 4.9% | ||
| Q3 25 | 20.9% | 3.5% | ||
| Q2 25 | -18.7% | 8.6% | ||
| Q1 25 | 6.0% | -14.0% | ||
| Q4 24 | -2.8% | -32.6% | ||
| Q3 24 | -16.5% | -43.0% | ||
| Q2 24 | 17.0% | -6.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 2.7% | ||
| Q3 25 | 0.2% | 4.5% | ||
| Q2 25 | 1.6% | 1.1% | ||
| Q1 25 | 0.2% | 2.1% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.3% | 5.1% | ||
| Q2 24 | 0.9% | 3.3% |
| Q1 26 | — | — | ||
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
MXL
Segment breakdown not available.
